TY - JOUR T1 - Limitations of a 6-min walk test to assess the efficacy of menthol for breathlessness JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00090-2022 VL - 8 IS - 2 SP - 00090-2022 AU - Masashi Kanezaki AU - Satoru Ebihara Y1 - 2022/04/01 UR - http://openres.ersjournals.com/content/8/2/00090-2022.abstract N2 - Walking is a vital component of physical activity in patients with chronic obstructive pulmonary disease (COPD). Exertional multidimensional breathlessness in daily life can reduce walking speed and time in patients with established COPD [1]. Improvement in breathlessness beyond a minimal clinically significant difference brought about by pulmonary rehabilitation, pharmaceutical bronchodilators and opioids has been reported [2–4]. However, despite guideline-directed disease-specific therapy, some patients with COPD experience residual breathlessness. Therefore, the application of a novel symptom-based treatment that is widely available will benefit patients with long-term breathlessness.l-Menthol is a novel treatment option for breathlessness in patients with COPD. However, the clinical application of menthol for the treatment of exertional breathlessness in these patients warrants further research. https://bit.ly/3D6rLiJ ER -